Trial Profile

A clinical trial of Epetraborole for treatment for patients with non-tuberculous mycobacterial (NTM) lung disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jan 2022 New trial record
20 Jan 2022 According to AN2 Therapeutics media release, U.S. Food and Drug Administration cleared the Company's Investigational New Drug application for epetraborole, treatment for patients with non-tuberculous mycobacterial lung disease in December. In addition, the FDA also granted Qualified Infectious Disease Product (QIDP) and Fast Track Designation for the development of epetraborole in treatment-refractory Mycobacterium avium complex lung disease in December.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com